High-doses of Covid medicines not effective in India than Europe
Written By : Preksha garg
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-12-02 03:30 GMT | Update On 2023-12-02 03:30 GMT
Advertisement
According to a new study published in The Lancet Regional Health - Southeast Asia journal higher doses of the COVID-19 drug, dexamethasone, may have less beneficial effects for patients in India as compared with those in Europe,
The researchers in the study evaluated how strong dose of dexamethasone worked for COVID-19 patients. It considered factors like patient differences and health systems.
Their team, including researchers from Copenhagen University Hospital - Rigshospitalet, Denmark found that bigger dose of dexamethasone (12 mg) did not seem to be as good as the usual dose (6 mg) for COVID-19 patients in India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.